Open88.900 | Close- |
Vol / Avg.20.845K / 292.585K | Mkt Cap4.499B |
Day Range88.130 - 89.500 | 52 Wk Range72.260 - 95.260 |
Haemonetics Stock (NYSE: HAE) stock price, news, charts, stock research, profile.
Open88.900 | Close- |
Vol / Avg.20.845K / 292.585K | Mkt Cap4.499B |
Day Range88.130 - 89.500 | 52 Wk Range72.260 - 95.260 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.890 | (EXPECTED) 2023-11-06 | |||||
REV | 313.560M |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.760 | 1.050 | 0.2900 | ||||
REV | 297.920M | 311.332M | 13.412M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 111.00 | 114.00 |
2023-05-12 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 103.00 | 111.00 |
2023-05-12 | Morgan Stanley | Drew Ranieri | Maintains | Equal-WeightEqual-Weight | Raises | 88.00 | 96.00 |
2023-05-12 | JMP Securities | David Turkaly | Maintains | Market OutperformMarket Outperform | Raises | 105.00 | 115.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
HAE | Haemonetics | -0.97% | 4.5B |
TELA | TELA Bio | -5.13% | 185.9M |
RXST | RxSight | 0% | 994.1M |
EMBC | Embecta | -1.46% | 849.8M |
ALGN | Align Tech | -1.22% | 23.1B |
You can purchase shares of Haemonetics (NYSE: HAE) through any online brokerage.
Other companies in Haemonetics’s space includes: TELA Bio (NASDAQ:TELA), RxSight (NASDAQ:RXST), Embecta (NASDAQ:EMBC), Align Tech (NASDAQ:ALGN) and ICU Medical (NASDAQ:ICUI).
The latest price target for Haemonetics (NYSE: HAE) was reported by Barrington Research on Wednesday, August 9, 2023. The analyst firm set a price target for 114.00 expecting HAE to rise to within 12 months (a possible 28.51% upside). 19 analyst firms have reported ratings in the last year.
The stock price for Haemonetics (NYSE: HAE) is $88.71 last updated Today at October 2, 2023 at 3:19 PM UTC.
There is no dividend information for Haemonetics.
Haemonetics’s Q2 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Haemonetics.
Haemonetics is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NYSE.
Haemonetics Stock (NYSE: HAE) stock price, news, charts, stock research, profile.
Open88.900 | Close- |
Vol / Avg.20.845K / 292.585K | Mkt Cap4.499B |
Day Range88.130 - 89.500 | 52 Wk Range72.260 - 95.260 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.890 | (EXPECTED) 2023-11-06 | |||||
REV | 313.560M |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.760 | 1.050 | 0.2900 | ||||
REV | 297.920M | 311.332M | 13.412M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 111.00 | 114.00 |
2023-05-12 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 103.00 | 111.00 |
2023-05-12 | Morgan Stanley | Drew Ranieri | Maintains | Equal-WeightEqual-Weight | Raises | 88.00 | 96.00 |
2023-05-12 | JMP Securities | David Turkaly | Maintains | Market OutperformMarket Outperform | Raises | 105.00 | 115.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
HAE | Haemonetics | -0.97% | 4.5B |
TELA | TELA Bio | -5.13% | 185.9M |
RXST | RxSight | 0% | 994.1M |
EMBC | Embecta | -1.46% | 849.8M |
ALGN | Align Tech | -1.22% | 23.1B |
You can purchase shares of Haemonetics (NYSE: HAE) through any online brokerage.
Other companies in Haemonetics’s space includes: TELA Bio (NASDAQ:TELA), RxSight (NASDAQ:RXST), Embecta (NASDAQ:EMBC), Align Tech (NASDAQ:ALGN) and ICU Medical (NASDAQ:ICUI).
The latest price target for Haemonetics (NYSE: HAE) was reported by Barrington Research on Wednesday, August 9, 2023. The analyst firm set a price target for 114.00 expecting HAE to rise to within 12 months (a possible 28.51% upside). 19 analyst firms have reported ratings in the last year.
The stock price for Haemonetics (NYSE: HAE) is $88.71 last updated Today at October 2, 2023 at 3:19 PM UTC.
There is no dividend information for Haemonetics.
Haemonetics’s Q2 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Haemonetics.
Haemonetics is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NYSE.
Haemonetics Stock (NYSE: HAE) stock price, news, charts, stock research, profile.
Open88.900 | Close- |
Vol / Avg.20.845K / 292.585K | Mkt Cap4.499B |
Day Range88.130 - 89.500 | 52 Wk Range72.260 - 95.260 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.890 | (EXPECTED) 2023-11-06 | |||||
REV | 313.560M |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.760 | 1.050 | 0.2900 | ||||
REV | 297.920M | 311.332M | 13.412M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 111.00 | 114.00 |
2023-05-12 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 103.00 | 111.00 |
2023-05-12 | Morgan Stanley | Drew Ranieri | Maintains | Equal-WeightEqual-Weight | Raises | 88.00 | 96.00 |
2023-05-12 | JMP Securities | David Turkaly | Maintains | Market OutperformMarket Outperform | Raises | 105.00 | 115.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
HAE | Haemonetics | -0.97% | 4.5B |
TELA | TELA Bio | -5.13% | 185.9M |
RXST | RxSight | 0% | 994.1M |
EMBC | Embecta | -1.46% | 849.8M |
ALGN | Align Tech | -1.22% | 23.1B |
You can purchase shares of Haemonetics (NYSE: HAE) through any online brokerage.
Other companies in Haemonetics’s space includes: TELA Bio (NASDAQ:TELA), RxSight (NASDAQ:RXST), Embecta (NASDAQ:EMBC), Align Tech (NASDAQ:ALGN) and ICU Medical (NASDAQ:ICUI).
The latest price target for Haemonetics (NYSE: HAE) was reported by Barrington Research on Wednesday, August 9, 2023. The analyst firm set a price target for 114.00 expecting HAE to rise to within 12 months (a possible 28.51% upside). 19 analyst firms have reported ratings in the last year.
The stock price for Haemonetics (NYSE: HAE) is $88.71 last updated Today at October 2, 2023 at 3:19 PM UTC.
There is no dividend information for Haemonetics.
Haemonetics’s Q2 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Haemonetics.
Haemonetics is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NYSE.
Haemonetics Stock (NYSE: HAE) stock price, news, charts, stock research, profile.
Open88.900 | Close- |
Vol / Avg.20.845K / 292.585K | Mkt Cap4.499B |
Day Range88.130 - 89.500 | 52 Wk Range72.260 - 95.260 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.890 | (EXPECTED) 2023-11-06 | |||||
REV | 313.560M |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.760 | 1.050 | 0.2900 | ||||
REV | 297.920M | 311.332M | 13.412M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 111.00 | 114.00 |
2023-05-12 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 103.00 | 111.00 |
2023-05-12 | Morgan Stanley | Drew Ranieri | Maintains | Equal-WeightEqual-Weight | Raises | 88.00 | 96.00 |
2023-05-12 | JMP Securities | David Turkaly | Maintains | Market OutperformMarket Outperform | Raises | 105.00 | 115.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
HAE | Haemonetics | -0.97% | 4.5B |
TELA | TELA Bio | -5.13% | 185.9M |
RXST | RxSight | 0% | 994.1M |
EMBC | Embecta | -1.46% | 849.8M |
ALGN | Align Tech | -1.22% | 23.1B |
You can purchase shares of Haemonetics (NYSE: HAE) through any online brokerage.
Other companies in Haemonetics’s space includes: TELA Bio (NASDAQ:TELA), RxSight (NASDAQ:RXST), Embecta (NASDAQ:EMBC), Align Tech (NASDAQ:ALGN) and ICU Medical (NASDAQ:ICUI).
The latest price target for Haemonetics (NYSE: HAE) was reported by Barrington Research on Wednesday, August 9, 2023. The analyst firm set a price target for 114.00 expecting HAE to rise to within 12 months (a possible 28.51% upside). 19 analyst firms have reported ratings in the last year.
The stock price for Haemonetics (NYSE: HAE) is $88.71 last updated Today at October 2, 2023 at 3:19 PM UTC.
There is no dividend information for Haemonetics.
Haemonetics’s Q2 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Haemonetics.
Haemonetics is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NYSE.
Haemonetics Stock (NYSE: HAE) stock price, news, charts, stock research, profile.
Open88.900 | Close- |
Vol / Avg.20.845K / 292.585K | Mkt Cap4.499B |
Day Range88.130 - 89.500 | 52 Wk Range72.260 - 95.260 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.890 | (EXPECTED) 2023-11-06 | |||||
REV | 313.560M |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.760 | 1.050 | 0.2900 | ||||
REV | 297.920M | 311.332M | 13.412M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 111.00 | 114.00 |
2023-05-12 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 103.00 | 111.00 |
2023-05-12 | Morgan Stanley | Drew Ranieri | Maintains | Equal-WeightEqual-Weight | Raises | 88.00 | 96.00 |
2023-05-12 | JMP Securities | David Turkaly | Maintains | Market OutperformMarket Outperform | Raises | 105.00 | 115.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
HAE | Haemonetics | -0.97% | 4.5B |
TELA | TELA Bio | -5.13% | 185.9M |
RXST | RxSight | 0% | 994.1M |
EMBC | Embecta | -1.46% | 849.8M |
ALGN | Align Tech | -1.22% | 23.1B |
You can purchase shares of Haemonetics (NYSE: HAE) through any online brokerage.
Other companies in Haemonetics’s space includes: TELA Bio (NASDAQ:TELA), RxSight (NASDAQ:RXST), Embecta (NASDAQ:EMBC), Align Tech (NASDAQ:ALGN) and ICU Medical (NASDAQ:ICUI).
The latest price target for Haemonetics (NYSE: HAE) was reported by Barrington Research on Wednesday, August 9, 2023. The analyst firm set a price target for 114.00 expecting HAE to rise to within 12 months (a possible 28.51% upside). 19 analyst firms have reported ratings in the last year.
The stock price for Haemonetics (NYSE: HAE) is $88.71 last updated Today at October 2, 2023 at 3:19 PM UTC.
There is no dividend information for Haemonetics.
Haemonetics’s Q2 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Haemonetics.
Haemonetics is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NYSE.
Haemonetics Stock (NYSE: HAE) stock price, news, charts, stock research, profile.
Open88.900 | Close- |
Vol / Avg.20.845K / 292.585K | Mkt Cap4.499B |
Day Range88.130 - 89.500 | 52 Wk Range72.260 - 95.260 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.890 | (EXPECTED) 2023-11-06 | |||||
REV | 313.560M |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.760 | 1.050 | 0.2900 | ||||
REV | 297.920M | 311.332M | 13.412M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 111.00 | 114.00 |
2023-05-12 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 103.00 | 111.00 |
2023-05-12 | Morgan Stanley | Drew Ranieri | Maintains | Equal-WeightEqual-Weight | Raises | 88.00 | 96.00 |
2023-05-12 | JMP Securities | David Turkaly | Maintains | Market OutperformMarket Outperform | Raises | 105.00 | 115.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
HAE | Haemonetics | -0.97% | 4.5B |
TELA | TELA Bio | -5.13% | 185.9M |
RXST | RxSight | 0% | 994.1M |
EMBC | Embecta | -1.46% | 849.8M |
ALGN | Align Tech | -1.22% | 23.1B |
You can purchase shares of Haemonetics (NYSE: HAE) through any online brokerage.
Other companies in Haemonetics’s space includes: TELA Bio (NASDAQ:TELA), RxSight (NASDAQ:RXST), Embecta (NASDAQ:EMBC), Align Tech (NASDAQ:ALGN) and ICU Medical (NASDAQ:ICUI).
The latest price target for Haemonetics (NYSE: HAE) was reported by Barrington Research on Wednesday, August 9, 2023. The analyst firm set a price target for 114.00 expecting HAE to rise to within 12 months (a possible 28.51% upside). 19 analyst firms have reported ratings in the last year.
The stock price for Haemonetics (NYSE: HAE) is $88.71 last updated Today at October 2, 2023 at 3:19 PM UTC.
There is no dividend information for Haemonetics.
Haemonetics’s Q2 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Haemonetics.
Haemonetics is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NYSE.
Haemonetics Stock (NYSE: HAE) stock price, news, charts, stock research, profile.
Open88.900 | Close- |
Vol / Avg.20.845K / 292.585K | Mkt Cap4.499B |
Day Range88.130 - 89.500 | 52 Wk Range72.260 - 95.260 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.890 | (EXPECTED) 2023-11-06 | |||||
REV | 313.560M |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.760 | 1.050 | 0.2900 | ||||
REV | 297.920M | 311.332M | 13.412M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 111.00 | 114.00 |
2023-05-12 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 103.00 | 111.00 |
2023-05-12 | Morgan Stanley | Drew Ranieri | Maintains | Equal-WeightEqual-Weight | Raises | 88.00 | 96.00 |
2023-05-12 | JMP Securities | David Turkaly | Maintains | Market OutperformMarket Outperform | Raises | 105.00 | 115.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
HAE | Haemonetics | -0.97% | 4.5B |
TELA | TELA Bio | -5.13% | 185.9M |
RXST | RxSight | 0% | 994.1M |
EMBC | Embecta | -1.46% | 849.8M |
ALGN | Align Tech | -1.22% | 23.1B |
You can purchase shares of Haemonetics (NYSE: HAE) through any online brokerage.
Other companies in Haemonetics’s space includes: TELA Bio (NASDAQ:TELA), RxSight (NASDAQ:RXST), Embecta (NASDAQ:EMBC), Align Tech (NASDAQ:ALGN) and ICU Medical (NASDAQ:ICUI).
The latest price target for Haemonetics (NYSE: HAE) was reported by Barrington Research on Wednesday, August 9, 2023. The analyst firm set a price target for 114.00 expecting HAE to rise to within 12 months (a possible 28.51% upside). 19 analyst firms have reported ratings in the last year.
The stock price for Haemonetics (NYSE: HAE) is $88.71 last updated Today at October 2, 2023 at 3:19 PM UTC.
There is no dividend information for Haemonetics.
Haemonetics’s Q2 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Haemonetics.
Haemonetics is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NYSE.
Haemonetics Stock (NYSE: HAE) stock price, news, charts, stock research, profile.
Open88.900 | Close- |
Vol / Avg.20.845K / 292.585K | Mkt Cap4.499B |
Day Range88.130 - 89.500 | 52 Wk Range72.260 - 95.260 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.890 | (EXPECTED) 2023-11-06 | |||||
REV | 313.560M |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.760 | 1.050 | 0.2900 | ||||
REV | 297.920M | 311.332M | 13.412M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 111.00 | 114.00 |
2023-05-12 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 103.00 | 111.00 |
2023-05-12 | Morgan Stanley | Drew Ranieri | Maintains | Equal-WeightEqual-Weight | Raises | 88.00 | 96.00 |
2023-05-12 | JMP Securities | David Turkaly | Maintains | Market OutperformMarket Outperform | Raises | 105.00 | 115.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
HAE | Haemonetics | -0.97% | 4.5B |
TELA | TELA Bio | -5.13% | 185.9M |
RXST | RxSight | 0% | 994.1M |
EMBC | Embecta | -1.46% | 849.8M |
ALGN | Align Tech | -1.22% | 23.1B |
You can purchase shares of Haemonetics (NYSE: HAE) through any online brokerage.
Other companies in Haemonetics’s space includes: TELA Bio (NASDAQ:TELA), RxSight (NASDAQ:RXST), Embecta (NASDAQ:EMBC), Align Tech (NASDAQ:ALGN) and ICU Medical (NASDAQ:ICUI).
The latest price target for Haemonetics (NYSE: HAE) was reported by Barrington Research on Wednesday, August 9, 2023. The analyst firm set a price target for 114.00 expecting HAE to rise to within 12 months (a possible 28.51% upside). 19 analyst firms have reported ratings in the last year.
The stock price for Haemonetics (NYSE: HAE) is $88.71 last updated Today at October 2, 2023 at 3:19 PM UTC.
There is no dividend information for Haemonetics.
Haemonetics’s Q2 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Haemonetics.
Haemonetics is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NYSE.
Haemonetics Stock (NYSE: HAE) stock price, news, charts, stock research, profile.
Open88.900 | Close- |
Vol / Avg.20.845K / 292.585K | Mkt Cap4.499B |
Day Range88.130 - 89.500 | 52 Wk Range72.260 - 95.260 |
Q2 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.890 | (EXPECTED) 2023-11-06 | |||||
REV | 313.560M |
Q1 2024 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.760 | 1.050 | 0.2900 | ||||
REV | 297.920M | 311.332M | 13.412M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-09 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 111.00 | 114.00 |
2023-05-12 | Barrington Research | Michael Petusky | Maintains | OutperformOutperform | Raises | 103.00 | 111.00 |
2023-05-12 | Morgan Stanley | Drew Ranieri | Maintains | Equal-WeightEqual-Weight | Raises | 88.00 | 96.00 |
2023-05-12 | JMP Securities | David Turkaly | Maintains | Market OutperformMarket Outperform | Raises | 105.00 | 115.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
HAE | Haemonetics | -0.97% | 4.5B |
TELA | TELA Bio | -5.13% | 185.9M |
RXST | RxSight | 0% | 994.1M |
EMBC | Embecta | -1.46% | 849.8M |
ALGN | Align Tech | -1.22% | 23.1B |
You can purchase shares of Haemonetics (NYSE: HAE) through any online brokerage.
Other companies in Haemonetics’s space includes: TELA Bio (NASDAQ:TELA), RxSight (NASDAQ:RXST), Embecta (NASDAQ:EMBC), Align Tech (NASDAQ:ALGN) and ICU Medical (NASDAQ:ICUI).
The latest price target for Haemonetics (NYSE: HAE) was reported by Barrington Research on Wednesday, August 9, 2023. The analyst firm set a price target for 114.00 expecting HAE to rise to within 12 months (a possible 28.51% upside). 19 analyst firms have reported ratings in the last year.
The stock price for Haemonetics (NYSE: HAE) is $88.71 last updated Today at October 2, 2023 at 3:19 PM UTC.
There is no dividend information for Haemonetics.
Haemonetics’s Q2 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Haemonetics.
Haemonetics is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NYSE.